Maryland Capital Advisors Inc. Pharma Cyte Biotech, Inc. Transaction History
Maryland Capital Advisors Inc.
- $203 Million
- Q3 2024
A detailed history of Maryland Capital Advisors Inc. transactions in Pharma Cyte Biotech, Inc. stock. As of the latest transaction made, Maryland Capital Advisors Inc. holds 35 shares of PMCB stock, worth $62. This represents 0.0% of its overall portfolio holdings.
Number of Shares
35Holding current value
$62% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding PMCB
# of Institutions
31Shares Held
1.12MCall Options Held
0Put Options Held
0-
K2 Principal Fund, L.P. Toronto, A6328KShares$586,2300.33% of portfolio
-
Vanguard Group Inc Valley Forge, PA192KShares$344,3720.0% of portfolio
-
Geode Capital Management, LLC Boston, MA177KShares$316,1220.0% of portfolio
-
Ayrton Capital LLC Westport, CT92.1KShares$164,8357.31% of portfolio
-
Equitec Proprietary Markets, LLC82.7KShares$148,0810.17% of portfolio
About PharmaCyte Biotech, Inc.
- Ticker PMCB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,750,100
- Market Cap $37.1M
- Description
- PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types o...